These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 823954)

  • 1. Ages and frequencies for cervical cancer screening.
    Knox EG
    Br J Cancer; 1976 Oct; 34(4):444-52. PubMed ID: 823954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England.
    Simonella L; Canfell K
    Cancer Causes Control; 2013 Sep; 24(9):1727-36. PubMed ID: 23832659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cervical cancer epidemic that screening has prevented in the UK.
    Peto J; Gilham C; Fletcher O; Matthews FE
    Lancet; 2004 Jul 17-23; 364(9430):249-56. PubMed ID: 15262102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality from carcinoma of cervix uteri in Britain.
    Macgregor JE; Teper S
    Lancet; 1978 Oct; 2(8093):774-6. PubMed ID: 80695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in mortality from uterine cancer in relation to mass screening.
    Christopherson WM; Scott MA
    Acta Cytol; 1977; 21(1):5-9. PubMed ID: 264759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2012 Jun; 156(12):880-91, W312. PubMed ID: 22711081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model.
    Parkin DM; Moss SM
    J Epidemiol Community Health; 1986 Jun; 40(2):143-53. PubMed ID: 3746177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.
    Martin-Hirsch P; Rash B; Martin A; Standaert B
    BJOG; 2007 Apr; 114(4):408-15. PubMed ID: 17378815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of saving a life through cervical cytology screening: implications for health policy.
    Charny MC; Farrow SC; Roberts CJ
    Health Policy; 1987 Jun; 7(3):345-59. PubMed ID: 10282698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
    J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rising cervical cancer mortality in young New Zealand women.
    Green GH
    N Z Med J; 1979 Feb; 89(629):89-91. PubMed ID: 286218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China].
    Xu H; Zhao FH; Gao XH; Hu SY; Chen JF; Liu ZH; Xu XL; Gao LM; Liu QG; Ma L; Liu YJ; Qiao YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Apr; 34(4):399-403. PubMed ID: 23937850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact on women's health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium.
    Tjalma WAA; Kim E; Vandeweyer K
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():171-181. PubMed ID: 28081908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model.
    Sasieni P; Adams J
    BMJ; 1999 May; 318(7193):1244-5. PubMed ID: 10231253
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should endocervical curettage routinely be performed at the time of colposcopy? A cost-effectiveness analysis.
    Shepherd JP; Guido R; Lowder JL
    J Low Genit Tract Dis; 2014 Apr; 18(2):101-8. PubMed ID: 24270197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of cervical cytology?
    Lees TW
    Lancet; 1969 May; 1(7603):1020. PubMed ID: 4181175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.